CRVS
Corvus Pharmaceuticals, Inc. [CRVS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CRVS Stock Summary
Top 10 Correlated ETFs
CRVS
Top 10 Correlated Stocks
CRVS
In the News
CRVS Financial details
Company Rating
Neutral
Market Cap
75.03M
Income
-27.95M
Revenue
0
Book val./share
0.79
Cash/share
0.55
Dividend
-
Dividend %
-
Employees
28
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-3.15
Forward P/E
-
PEG
0.69
P/S
-
P/B
2.66
P/C
2.58
P/FCF
-4.48
Quick Ratio
4.41
Current Ratio
4.53
Debt / Equity
0.04
LT Debt / Equity
-
-
-
EPS (TTM)
-0.59
EPS next Y
-
EPS next Q
-
EPS this Y
-48.15%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
16.67%
-
-
-
-
SMA20
-50%
SMA50
-50%
SMA100
-
Inst Own
37.83%
Inst Trans
0.91%
ROA
-72%
ROE
-75%
ROC
-0.52%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.977-4.19
52W High
-
52W Low
-
RSI
31
Rel Volume
0.19
Avg Volume
205.85K
Volume
39.91K
Perf Week
-8.97%
Perf Month
-33.02%
Perf Quarter
26.79%
Perf Half Y
2.9%
-
-
-
-
Beta
1.018
-
-
Volatility
0.05%, 0.2%
Prev Close
0.71%
Price
1.42
Change
2.9%
CRVS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -1.49 | -0.16 | -0.91 | -1.08 | -0.56 | |
| Operating cash flow per share | -1.27 | -1.18 | -0.88 | -0.58 | -0.5 | |
| Free cash flow per share | -1.27 | -1.18 | -0.88 | -0.59 | -0.5 | |
| Cash per share | 2.66 | 1.5 | 1.66 | 0.91 | 0.57 | |
| Book value per share | 2.42 | 2.45 | 2.32 | 1.21 | 0.81 | |
| Tangible book value per share | 2.42 | 2.45 | 2.32 | 1.21 | 0.81 | |
| Share holders equity per share | 2.42 | 2.45 | 2.32 | 1.21 | 0.81 | |
| Interest debt per share | 0.26 | 0.14 | 0.15 | 0.1 | 0.06 | |
| Market cap | 159.66M | 104.94M | 100.87M | 39.57M | 84.52M | |
| Enterprise value | 157.7M | 90.8M | 41.06M | 29.01M | 73.28M | |
| P/E ratio | -3.65 | -21.76 | -2.64 | -0.79 | -3.13 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -4.28 | -3.02 | -2.75 | -1.46 | -3.53 | |
| PFCF ratio | -4.28 | -3.01 | -2.75 | -1.45 | -3.53 | |
| P/B Ratio | 2.25 | 1.45 | 1.04 | 0.71 | 2.18 | |
| PTB ratio | 2.25 | 1.45 | 1.04 | 0.71 | 2.18 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -3.23 | -2.07 | -0.95 | -0.89 | -3.15 | |
| EV to operating cash flow | -4.23 | -2.61 | -1.12 | -1.07 | -3.06 | |
| EV to free cash flow | -4.22 | -2.61 | -1.12 | -1.06 | -3.06 | |
| Earnings yield | -0.27 | -0.05 | -0.38 | -1.26 | -0.32 | |
| Free cash flow yield | -0.23 | -0.33 | -0.36 | -0.69 | -0.28 | |
| Debt to equity | 0.08 | 0.05 | 0.06 | 0.07 | 0.04 | |
| Debt to assets | 0.07 | 0.04 | 0.06 | 0.06 | 0.03 | |
| Net debt to EBITDA | 0.04 | 0.32 | 1.38 | 0.32 | 0.48 | |
| Current ratio | 6.22 | 3.31 | 5.65 | 3.49 | 4.07 | |
| Interest coverage | -22.39 | -81.04 | -2.58K | -49.79 | -14.78 | |
| Income quality | 0.8 | 5.8 | 0.85 | 0.65 | 0.89 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0.01 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.03 | -0.12 | -0.01 | -0.73 | -0.23 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 9.01 | 3 | 6.9 | 5.4 | 3.19 | |
| ROIC | -0.57 | -0.45 | -0.32 | -0.63 | -0.56 | |
| Return on tangible assets | -0.52 | -0.06 | -0.35 | -0.73 | -0.59 | |
| Graham Net | 2.22 | 1.04 | 1.37 | 0.65 | 0.42 | |
| Working capital | 65.45M | 30.88M | 57.16M | 30.18M | 21.09M | |
| Tangible asset value | 71.11M | 72.15M | 97.16M | 56.12M | 38.68M | |
| Net current asset value | 65.45M | 30.88M | 57.16M | 30.18M | 21.09M | |
| Invested capital | 0.08 | 0.05 | 0.06 | 0.07 | 0.04 | |
| Average receivables | 333K | 207.5K | 312.5K | 586K | 348K | |
| Average payables | 2.22M | 2.96M | 2.52M | 1.77M | 1.75M | |
| Average inventory | -708.5K | -653.5K | -579.5K | -701K | -367.5K | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 1.2K | 2K | 1.24K | 1.97K | 3.69K | |
| Days of inventory on hand | -400.37 | -284.15 | -529.25 | -730.99 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.3 | 0.18 | 0.29 | 0.19 | 0.1 | |
| Inventory turnover | -0.91 | -1.28 | -0.69 | -0.5 | 0 | |
| ROE | -0.62 | -0.07 | -0.39 | -0.89 | -0.7 | |
| Capex per share | 0 | 0 | 0 | -0.01 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.35 | -0.19 | -0.14 | -0.12 | -0.14 | |
| Operating cash flow per share | -0.16 | -0.17 | -0.11 | -0.11 | -0.11 | |
| Free cash flow per share | -0.16 | -0.17 | -0.11 | -0.11 | -0.11 | |
| Cash per share | 0.91 | 0.74 | 0.78 | 0.66 | 0.55 | |
| Book value per share | 1.21 | 1.05 | 1.04 | 0.9 | 0.79 | |
| Tangible book value per share | 1.21 | 1.05 | 1.04 | 0.9 | 0.79 | |
| Share holders equity per share | 1.21 | 1.05 | 1.04 | 0.9 | 0.79 | |
| Interest debt per share | 0.09 | 0.08 | 0.05 | 0.04 | 0.03 | |
| Market cap | 39.57M | 42.37M | 108.77M | 71.5M | 86.31M | |
| Enterprise value | 29.01M | 35.02M | 103.11M | 53.08M | 75.06M | |
| P/E ratio | -0.61 | -1.2 | -4.18 | -2.98 | -3.24 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -5.24 | -5.22 | -20.83 | -13.16 | -16.7 | |
| PFCF ratio | -5.24 | -5.2 | -20.83 | -13.16 | -16.7 | |
| P/B Ratio | 0.71 | 0.87 | 2.2 | 1.61 | 2.23 | |
| PTB ratio | 0.71 | 0.87 | 2.2 | 1.61 | 2.23 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -5.1 | -5.33 | -18.46 | -9.6 | -13.35 | |
| EV to operating cash flow | -3.84 | -4.32 | -19.74 | -9.77 | -14.53 | |
| EV to free cash flow | -3.84 | -4.3 | -19.74 | -9.77 | -14.53 | |
| Earnings yield | -0.41 | -0.21 | -0.06 | -0.08 | -0.08 | |
| Free cash flow yield | -0.19 | -0.19 | -0.05 | -0.08 | -0.06 | |
| Debt to equity | 0.07 | 0.07 | 0.04 | 0.04 | 0.04 | |
| Debt to assets | 0.06 | 0.06 | 0.03 | 0.03 | 0.03 | |
| Net debt to EBITDA | 1.86 | 1.12 | 1.01 | 3.33 | 2 | |
| Current ratio | 3.49 | 4.9 | 4.82 | 4.53 | 4.07 | |
| Interest coverage | -13.21 | -17.48 | -13.95 | -13.08 | 0 | |
| Income quality | 0.77 | 1.03 | 0.8 | 0.91 | 0.78 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.04 | -0.6 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 3.07 | 2.11 | 1.79 | 1.58 | 1.55 | |
| ROIC | -0.15 | -0.13 | -0.1 | -0.11 | -0.14 | |
| Return on tangible assets | -0.24 | -0.15 | -0.11 | -0.12 | -0.15 | |
| Graham Net | 0.65 | 0.54 | 0.61 | 0.51 | 0.41 | |
| Working capital | 30.18M | 27.44M | 30.05M | 25.8M | 21.09M | |
| Tangible asset value | 56.12M | 48.87M | 49.48M | 44.29M | 38.68M | |
| Net current asset value | 30.18M | 25.14M | 29.35M | 25.44M | 21.09M | |
| Invested capital | 0.07 | 0.07 | 0.04 | 0.04 | 0.04 | |
| Average receivables | 583.5K | 550K | 250.5K | 42K | 56.5K | |
| Average payables | 3.1M | 4.5M | 4.56M | 1.75M | 1.46M | |
| Average inventory | -5.5K | -666.5K | 62.5K | 692.5K | 331K | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 1.89K | 11.1K | 5.25K | 4.21K | 4.9K | |
| Days of inventory on hand | -703.72 | -944.21 | 1.81K | 1.99K | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.05 | 0.01 | 0.02 | 0.02 | 0.02 | |
| Inventory turnover | -0.13 | -0.1 | 0.05 | 0.05 | 0 | |
| ROE | -0.29 | -0.18 | -0.13 | -0.14 | -0.17 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
CRVS Frequently Asked Questions
What is Corvus Pharmaceuticals, Inc. stock symbol ?
Corvus Pharmaceuticals, Inc. is a US stock , located in Burlingame of Ca and trading under the symbol CRVS
What is Corvus Pharmaceuticals, Inc. stock quote today ?
Corvus Pharmaceuticals, Inc. stock price is $1.42 today.
Is Corvus Pharmaceuticals, Inc. stock public?
Yes, Corvus Pharmaceuticals, Inc. is a publicly traded company.
Company Profile
- Volume Average 205.85K
- Market Capitalization 75.03M
- Employee 28
- CEO Dr. Richard A. Miller M.D.
- Headquarters Burlingame,CA,US
- IPO Date 2016-03-23
-
Website
https://www.corvuspharma.com 
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
